Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
7-methyl-GpppA is a synthetic cap analog of the natural 5' cap structure found on eukaryotic messenger RNA (mRNA). Chemically, it is a dinucleotide composed of 7-methylguanosine linked via a triphosphate bridge to adenosine. This molecule mimics the natural mRNA cap structure and can be incorporated into synthetic or in vitro transcribed mRNAs. Its primary use is as a research tool to study mechanisms of translation initiation, RNA stability, and interactions with proteins such as eukaryotic initiation factor 4E (eIF4E), which recognizes and binds the methylated guanosine cap during translation initiation. It also serves as a substrate for enzymes involved in mRNA decapping and degradation pathways[1][2][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 7-methyl-GpppA.